First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo

First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo
The first participant has been dosed in the Phase 2 clinical trial IRENE, which is evaluating Incyte's immunotherapy retifanlimab in combination with the oncolytic virus pelareorep, by Oncolytics Biotech, as a treatment for locally advanced or metastatic triple-negative breast cancer (TNBC). The trial (NCT04445844) is currently recruiting patients at the Rutgers Cancer Institute of New Jersey, and is planning to also enroll participants at The Ohio State University Comprehensive Cancer Center. Additional information is available here. "The paucity of treatment options in metastatic triple-negative breast cancer combined with its aggressive clinical behavior results in a poorer prognosis when compared to other subtypes of breast cancer," Mridula George, MD, a medical oncologist at Rutgers Cancer Institute of New Jersey and investigator on the clinical trial, said in a press release. "I'm looking forward to getting this study un
Subscribe or to access all post and page content.